الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 82 |  |  |
| | | from | 82 | | |
Abstract
Hypertensive disorders with pregnancy complicate about 5–10 % of all pregnancies. In developed countries, one of the most common causes of maternal death is preeclampsia when untreated as it can lead to seizures (eclampsia), renal dysfunction, liver damage, respiratory and cardiac failure. Magnesium sulfate (MgSO4) is the drug of choice for both prevention and treatment of Eclampsia and is superior to either diazepam or phenytoin. Currently, the World Health Organization (WHO) recommends two MgSO4 regimens for eclampsia prophylaxis, namely the Pritchard regimen which is predominantly administered intramuscularly and the Zuspan regimen which is administered intravenously. The aim of the study is to compare between two different protocols of magnesium sulfate administration for prevention and management of fits with individualized dose adjustments. 100 pregnant women presented with severe preeclampsia/eclampsia who met the inclusion criteria will be enrolled after providing an informed and verbal consent and discussing the study procedure. Written informed consent will be obtained from those who agree to participate. All women will be examined at the time of admission after getting a detailed history. Complete blood counts, liver and renal function tests, and urine protein measurements will also be performedMagnesium sulfate will be measured for all patients at 0 ,12 ,24 and 36 hrs. after administration. All women are monitored for the entire duration of MgSO4 infusion for blood pressure, patellar reflexes, respiratory rate, urine output, and reoccurrence of convulsions. In the case of MgSO4 toxic effects, the plan of management is to stop further infusions of MgSO4, to inject 1 g of calcium gluconate(10 mL of 10% solution) intravenously, and to switch the therapy to another anticonvulsant. These patients are considered to have treatment failure and requiring another dose. There were no statistically significant differences in age, BMI,gestational age, parity and mode of delivery. There were no statistically significant differences in serum concentration of liver enzymes creatinene and degree of proteinuria. In conclusion, the present trial showed that Individualization of magnesium sulfate dose in preeclampsia/eclampsia is a promising alternative protocol to the standard protocol in preventing eclampsia in our population sample.